Detalhe da pesquisa
1.
Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms.
Int J Mol Sci
; 24(16)2023 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37628880
2.
The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia.
Hematol Rep
; 16(1): 140-150, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38534885
3.
DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study.
Thromb Haemost
; 2024 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38190984
4.
Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment.
Cancers (Basel)
; 15(13)2023 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37444494
5.
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.
Cancers (Basel)
; 15(4)2023 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36831388
6.
Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
World J Clin Oncol
; 11(12): 996-1007, 2020 Dec 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33437662
7.
Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations.
Cancers (Basel)
; 12(4)2020 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32290079